Tech Center 1600 • Art Units: 1651
This examiner grants 37% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16614133 | BIOFERTILIZER AND METHODS OF MAKING AND USING SAME | Non-Final OA | President and Fellows of Harvard College |
| 17686766 | MAMMALIAN CELL CULTURE | Non-Final OA | Amgen Inc. |
| 17442776 | PROBIOTIC BACTERIA CAPABLE OF ADAPTIVE RESPONSE TO POMEGRANATE EXTRACT AND METHODS OF PRODUCTION AND USE THEREOF | Final Rejection | North Carolina State University |
| 17080505 | Methods for purification of polypeptides using polysorbates | Final Rejection | Hoffmann-La Roche Inc. |
| 19211375 | COMPOUND MICROBIAL INOCULUM WITH BACTERIOSTATIC EFFECT AND USE THEREOF IN PREPARATION OF YOGURT | Final Rejection | SHIHEZI UNIVERSITY |
| 18246966 | BIOCATALYTIC PRODUCTION OF PARA-HYDROXYBENZOIC ACID FROM METHANOL AND METHANE | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17765960 | PURIFICATION OF PROTEINS AND VIRAL INACTIVATION | Non-Final OA | MERCK PATENT GMBH |
| 18547468 | METHODS FOR LIGATION OF (POLY)PEPTIDES AND OLIGONUCLEOTIDES | Non-Final OA | Nanyang Technological University |
| 17621497 | RATIOMETRIC DETECTION OF LUCIFERASE ASSAYS USING A CALIBRATOR LUCIFERASE | Non-Final OA | TECHNISCHE UNIVERSITEIT EINDHOVEN |
| 18073511 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | Non-Final OA | MarvelBiome, Inc. |
| 18776658 | LOCTOBACILLUS PLANTARUM 121-5 AND APPLICATION THEREOF IN PREPARING RESVERATROL BY CONVERTING POLYDATIN | Non-Final OA | SHAANXI INSTITUTE OF MICROBIOLOGY |
| 18231204 | SPRAY DRIED EXTRACT | Non-Final OA | Sutro Biopharma, Inc. |
| 17625468 | PROCESS FOR ISOLATING A HIGH PURITY PROTEIN PREPARATION FROM PLANT MATERIAL AND PRODUCTS THEREOF | Non-Final OA | PLANTIBLE FOODS, INC. |
| 17256813 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Non-Final OA | Givaudan SA |
| 18262523 | DETECTING BETA-LACTAMASE ENZYME ACTIVITY | Non-Final OA | UNIVERSITE PARIS-SACLAY |
| 17438025 | STORAGE LIQUID FOR MAMMALIAN CELLS | Non-Final OA | OTSUKA PHARMACEUTICAL FACTORY, INC. |
| 18117163 | Improved Cellulose to Cellobiose Conversion Process | Non-Final OA | SixRing Inc. |
| 18391729 | A PROBIOTIC COMPOSITION FOR IMPROVING WHEY PROTEIN PROTEOLYSIS, AUGMENTING AMINO ACID PRODUCTION, AND IMPROVING LACTOSE DEGRADATION ABILITY | Non-Final OA | LACTOMASON CO., LTD. |
| 17292324 | MARKER FOR DIAGNOSING NEURODEGENERATIVE DISEASE, AND THERAPEUTIC COMPOSITION | Non-Final OA | Soonchunhyang University Industry Academy Cooperation Foundation |
| 17080078 | ADENO-ASSOCIATED VIRUS VECTOR MEDIATED GENE THERAPY FOR OPHTHALMIC DISEASES | Non-Final OA | Ocugen, Inc. |
| 17626168 | METHODS FOR MAKING RECOMBINANT PROTEIN | Non-Final OA | Monash University |
| 18348128 | MAD NUCLEASES | Non-Final OA | Inscripta, Inc. |
| 17767143 | COAGULATION ASSAY APPARATUS AND METHODS THEREOF | Final Rejection | Nova Biomedical Corporation |
| 18549558 | FORMULATION OF FUSION PROTEIN INCLUDING EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IGE FC RECEPTOR | Final Rejection | GI Innovation, Inc. |
| 18453221 | METHOD FOR EXPRESSING AND PURIFYING PROTEIN BY USING CSQ-TAG | Non-Final OA | ToolBio. Co |
| 18260861 | PROTEIN HAVING L-PROLINE EFFLUX FUNCTION, AND USE THEREOF | Final Rejection | TIANJIN INSTITUTE OF INDUSTRIAL BIOTECHNOLOGY, CHINESE ACADEMY OF SCIENCES |
| 18270856 | IMMUNOGENIC FUSION PROTEINS AGAINST INFECTIOUS ANIMAL DISEASES | Non-Final OA | NAVICURE BIOPHARMACEUTICALS LIMITED |
| 17290806 | SYSTEM AND METHOD FOR GENOME EDITING BASED ON C2C1 NUCLEASES | Non-Final OA | Institute of Zoology, Chinese Academy of Sciences |
| 17601125 | METHOD FOR EXPRESSING AND PURIFYING PROTEIN BY USING CSQ-TAG | Final Rejection | KOREA INSTITUTE OF CERAMIC ENGINEERING AND TECHNOLOGY |
| 18069452 | PERSIMMON DIETARY FIBER FOR ITS USE WITH OTHER BENEFICIAL MICROORGANISMS | Final Rejection | UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy